Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure

JACC: Heart Failure

Volumn 4, Issue 1, 2016, Pages 68-77

  Tang, W H Wilson ^a   Wu, Yuping ^b   Grodin, Justin L ^a   Hsu, Amy P ^a   Hernandez, Adrian F ^c   Butler, Javed ^d   Metra, Marco ^e   Voors, Adriaan A ^f   Felker, G Michael ^c   Troughton, Richard W ^g   Mills, Roger M ^h   McMurray, John J ⁱ   Armstrong, Paul W ^j   O'Connor, Christopher M ^c   Starling, Randall C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

Acute decompensated heart failure; Nesiritide; Prognosis; Soluble ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MEMBRANE PROTEIN; NESIRITIDE; PLACEBO; STIMULATION EXPRESSED GENE 2 PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFECT; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; HEART FAILURE; KAPLAN MEIER METHOD; METABOLISM; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BIOMARKERS; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; KAPLAN-MEIER ESTIMATE; MALE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84951741037     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.07.015     Document Type: Article

References (35)

1. Januzzi J.L. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 2013, 6:493-500.
2. Karayannis G., Triposkiadis F., Skoularigis J., Georgoulias P., Butler J., Giamouzis G. The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. Curr Heart Fail Rep 2013, 10:441-449.
3. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
4. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
5. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109:2186-2190.
6. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607-613.
7. Bartunek J., Delrue L., Van Durme F., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008, 52:2166-2174.
8. Rehman S.U., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008, 52:1458-1465.
9. Felker G.M., Fiuzat M., Thompson V., et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail 2013, 6:1172-1179.
10. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2:311-319.
11. Daniels L.B., Clopton P., Iqbal N., Tran K., Maisel A.S. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010, 160:721-728.
12. Weir R.A., Miller A.M., Murphy G.E., et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010, 55:243-250.
13. Ahmad T., Fiuzat M., Neely B., et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. J Am Coll Cardiol HF 2014, 2:260-268.
14. Pascual-Figal D.A., Ordonez-Llanos J., Tornel P.L., et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54:2174-2179.
15. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
16. Lassus J., Gayat E., Mueller C., et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013, 168:2186-2194.
17. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365:32-43.
18. Harrell F.E. Regression Modeling Strategies 2001, Springer, New York, NY.
19. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. discussion 207-12.
20. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
21. Dieplinger B., Januzzi J.L., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 2009, 409:33-40.
22. Wu A.H., Wians F., Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013, 165:995-999.
23. Manzano-Fernandez S., Januzzi J.L., Pastor-Perez F.J., et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 2012, 122:158-166.
24. Gruson D., Lepoutre T., Ahn S.A., Rousseau M.F. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol 2014, 172:e250-e252.
25. Gaggin H.K., Szymonifka J., Bhardwaj A., et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. J Am Coll Cardiol HF 2014, 2:65-72.
26. Bayes-Genis A., de Antonio M., Vila J., et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 2014, 63:158-166.
27. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008, 14:732-738.
28. Breidthardt T., Balmelli C., Twerenbold R., et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 2013, 19:821-828.
29. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725.
30. Kerr K.F., Wang Z., Janes H., McClelland R.L., Psaty B.M., Pepe M.S. Net reclassification indices for evaluating risk-prediction instruments: a critical review. Epidemiology 2014, 25:114-121.
31. Tang W.H., Dupont M., Hernandez A.F., et al. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. J Am Coll Cardiol HF 2015, 3:40-49.
32. Pascual-Figal D.A., Januzzi J.L. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015, 115:3B-7B.
33. Anand I.S., Rector T.S., Kuskowski M., Snider J., Cohn J.N. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail 2014, 7:418-426.
34. Kaye D.M., Mariani J.A., van Empel V., Maeder M.T. Determinants and implications of elevated soluble ST2 levels in heart failure. Int J Cardiol 2014, 176:1242-1243.
35. Wojtczak-Soska K., Sakowicz A., Pietrucha T., Lelonek M. Soluble ST2 protein in the short-term prognosis after hospitalization in chronic systolic heart failure. Kardiol Pol 2014, 72:725-734.